Adults with CKD, type 2 diabetes, and moderately increased albuminuria, calcium channel blockers D RAS blockade versus RAS blockade Table S73. Adults with CKD and chronic hyperkalemia, potassium binder versus placebo Table S74. Adults with CKD and chronic hyperkalemia, calcium polystyrene sulphonate (CPS) versus sodium polystyrene sulphonate (SPS) Table S75. Adults with CKD without diabetes, lower MAP (<92 mm Hg) target versus higher MAP (102 107 mm Hg) target Table S76. Adults with CKD and proteinuria (>1g/24 h for at least 3 months) without diabetes, low blood pressure target (<130/80 mm Hg) versus standard diastolic blood pressure target (<90 mm Hg) Table S77. Adults with CKD without diabetes, lower blood pressure target ( 120 mm Hg) versus standard blood pressure target Table S78. Adults 75 years of age with CKD without diabetes, lower blood pressure target ( 120 mm Hg) versus standard blood pressure target Table S79. Adults with CKD without diabetes, calcium channel blockers versus RASi Table S80. Adults with diabetes and CKD, ACEi or ARB monotherapy versus dual (ACEi D ARB) therapy Table S81. Adults with diabetes and CKD, diuretics D ACEi or ARB versus ACEi or ARB Table S82. Adults with diabetes and CKD, diuretics D calcium channel blockers versus ACEi or ARB D calcium channel blockers Table S83. Adults with diabetes and CKD, diuretics D ACEi or ARB versus ACEi or ARB D calcium channel blockers Table S84. Adults with diabetes and CKD, diuretics D ACEi or ARB D beta-blockers versus placebo plus standard of care Table S85. Adults with CKD, type 2 diabetes, and moderately increased albuminuria, calcium channel blocker versus ARB plus diuretics www.kidney-international.org contents Table S86. Adults with CKD, type 2 diabetes and albuminuria (AER >100 mg/24 h), direct renin inhibitor versus placebo Table S87. 